Literature DB >> 30485506

Epigenetic and metabolic alterations in human amniotic fluid stem cells induced to cardiomyogenic differentiation by DNA methyltransferases and p53 inhibitors.

Monika Gasiūnienė1, Anastasija Zubova1, Algirdas Utkus2, Rūta Navakauskienė1.   

Abstract

Human amniotic fluid-derived mesenchymal stem cells (AF-MSCs) may be a valuable source for cell therapy and regenerative medicine. In this study, the potential of DNA methyltransferases (DNMT) inhibitors Decitabine, Zebularine, RG108 alone or combined with Zebularine and p53 inhibitor Pifithrin-α to induce cardiomyogenic differentiation of AF-MSCs was investigated. Differentiation into cardiomyocyte-like cells initiation was indicated with all agents by changes in the cell phenotype, upregulation of the relative expression of the main cardiac genes (NKX2-5, TNNT2, MYH6, and DES) as well as of cardiac ion channels genes (sodium, calcium, and potassium) as determined by reverse-transcription quantitative polymerase chain reaction and the increase in Connexin43 levels as detected from Western blot and immunofluorescence data. Cellular energetics and mitochondrial function in induced cells were assessed using Seahorse analyzer and revealed the initiation of AF-MSCs metabolic transformation into cardiomyocyte-like cells. All used inducers were nontoxic to AF-MSCs, arrested cell cycle at the G0/G1 phase, and upregulated p53 and p21 expression. The relative expression of miR-34a and miR-145 that are related to cell cycle regulation was also observed. Furthermore, the evaluated levels of chromatin remodeling proteins enhancer of zeste homolog 2, suppressor of zeste 12 protein homolog, DNMT1, histone deacetylase 1 (HDAC1), HDAC2, and heterochromatin protein 1α, as well as the rate of activating histone modifications, exhibited rearrangements of chromatin after the induction of cardiomyogenic differentiation. In conclusion, we demonstrated that all explored DNMT and p53 inhibitors initiated cardiomyogenesis-related alterations in AF-MSCs through rather similar mechanisms but to a different extent providing useful insights for the future research and potential applications of AF-MSCs.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  amniotic fluid; cardiac; cell cycle; cell differentiation; chromatin; myocytes

Year:  2018        PMID: 30485506     DOI: 10.1002/jcb.28092

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  3 in total

1.  Angiotensin II and TGF-β1 Induce Alterations in Human Amniotic Fluid-Derived Mesenchymal Stem Cells Leading to Cardiomyogenic Differentiation Initiation.

Authors:  Monika Gasiūnienė; Gintautas Petkus; Dalius Matuzevičius; Dalius Navakauskas; Rūta Navakauskienė
Journal:  Int J Stem Cells       Date:  2019-07-31       Impact factor: 2.500

Review 2.  Amniotic Fluid Cells, Stem Cells, and p53: Can We Stereotype p53 Functions?

Authors:  Melissa Rodrigues; Christine Blattner; Liborio Stuppia
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

3.  The Effect of Angiotensin II, Retinoic Acid, EGCG, and Vitamin C on the Cardiomyogenic Differentiation Induction of Human Amniotic Fluid-Derived Mesenchymal Stem Cells.

Authors:  Monika Gasiūnienė; Elvina Valatkaitė; Aistė Navakauskaitė; Rūta Navakauskienė
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.